Skip to main content
. 2017 Mar 4;143(6):961–970. doi: 10.1007/s00432-017-2365-y

Fig. 4.

Fig. 4

a Progression-free survival for renal cancer patients treated for metastatic disease with sunitinib in the first- or second-line setting (n = 61). b Progression-free survival for renal cancer patients treated for metastatic disease with sorafenib in the first- or second-line setting (n = 45)